VISEN Pharmaceuticals announced that its Board granted a total of 514,068 share awards on 20 July 2026 to 19 senior management members and employees under the company’s post-IPO share award scheme. The awards carry no purchase price, and the closing market price on the grant date was HK$18.90 per share.

Key terms of the grant:

1. Vesting Schedule • 300,000 awards: 40 % vest evenly over four years beginning the first anniversary of the grant date; the remaining 60 % vest in three equal tranches upon achieving pre-set performance milestones. • 172,468 awards: vest in two equal annual tranches starting one year after the grant date. • 41,600 awards: vest in four equal annual tranches beginning one year after the grant date, conditional on performance targets.

2. Validity and Forfeiture All unvested awards expire on 21 March 2035, aligning with the 10-year term stipulated in the scheme. Any awards unvested by that date will be forfeited without consideration.

3. Performance and Clawback Provisions Vesting for certain grantees depends on company-level financial milestones and individual performance indicators. A clawback mechanism allows the Board to cancel or reclaim awards in cases such as misconduct, fraud, or breach of employment terms.

4. Scheme Capacity The scheme permits issuance of up to 2.40 million shares. After this grant, 1.56 million shares remain available, with 71,985 shares left under the service-provider sub-limit.

The Board stated that the equity incentives aim to align management and employee interests with long-term shareholder value, enhance retention, and reward contributions to the group’s development. The grant has been approved by the Board, including independent non-executive directors, and no shareholder approval is required under current Listing Rules.